Developer of vaccines that are designed to selectively and specifically generate effective antibody-inducing immune responses. The company's vaccines are based on its proprietary peptide chemistry technology, providing users with vaccines that are safer, more stable and less expensive than current vaccines.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Out of Business | 01-Jun-2013 | Completed | Out of Business | |||
3. Grant | 01-Feb-2009 | 00000 | Completed | Generating Revenue | ||
2. Grant | 01-May-2005 | $218K | Completed | Generating Revenue | ||
1. Accelerator/Incubator | Completed | Startup |